Abstract
* A new cephalosporin, ceftaroline fosamil (Teflaro), has been approved to treat acute bacterial skin infections caused by methicillin-resistant Staphylococcus aureus, as well as serious community-acquired bacterial pneumonia requiring hospitalization.
* Ceftaroline fosamil is administered as an IV infusion.